Update on SAR Studies Toward New COX-1 Selective Inhibitors

Title:Update on SAR Studies Toward New COX-1 Selective Inhibitors

Volume: 22 Issue: 37

Author(s): Paola Vitale, Antonio Scilimati and Maria Grazia Perrone

Affiliation:

Keywords: Cyclooxygenase (COX)-1, COX-2, structure-activity relationship(SAR), diarylheterocycles, benzanilides, arylpropanoic acids, stilbenes, NSAIDs.

Abstract: Few selective cyclooxygenase-1 (COX-1) inhibitors have been described up to now, although recent studies underlined the involvement of COX-1 in the carcinogenesis, pathogenesis of neuroinflammation, cardiovascular diseases and pain. Among the known COX-1 inhibitors none proved to be a good drug candidate, with the exception of mofezolac, that is clinically used as an analgesic drug. New selective inhibitors were very often discovered as a minor achievement during SAR investigations to discover selective COX-2 inhibitors (COXIBs). After a recognition of the new COX-1 inhibitors synthesized in the last five years, it was attempted to draw, for each chemical class, a structure which might highlight the determinant molecular features able to switch the selectivity towards the COX-1 isoform. Overall, this review could constitute a tool to a better design of novel selective COX-1 inhibitors, to be used in a disease theranostic approach targeting COX-1.

Cite this article as:

Vitale Paola, Scilimati Antonio and Perrone Grazia Maria, Update on SAR Studies Toward New COX-1 Selective Inhibitors, Current Medicinal Chemistry 2015; 22 (37) . https://dx.doi.org/10.2174/0929867322666151029104717